Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Paper
  • Published:

Will the experience with tamoxifen in breast cancer help define the role of antiandrogens in prostate cancer?

Prostate Cancer and Prostatic Diseases volume 4, pages 72–80 (2001)Cite this article

Abstract

Breast and prostate cancers are the two predominant hormone-responsive tumours. The use of the antioestrogen tamoxifen in the treatment of breast cancer has evolved over the past 30 y from treatment for advanced breast cancer to prevention. Tamoxifen is currently the endocrine treatment of choice for advanced breast cancer and for adjuvant therapy in a broad spectrum of women whose primary tumours have functional oestrogen receptors. It has also been shown to reduce the incidence of breast cancer in high-risk women. Non-steroidal antiandrogen therapy is used in the treatment of prostate cancer, but its role is still being defined. The clinical development of tamoxifen and that of the antiandrogens are reviewed and parallels are uncovered which provide insight into contemporary and future management of hormone-responsive prostate cancer.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Beatson G. On the treatment of inoperable carcinoma of the mamma: suggestion of a new method of treatment with illustrative cases. Lancet 1896 ii 102–107, 162–167.

    Google Scholar 

  2. Haddow A et al Influence of synthetic oestrogens upon advanced malignant disease. Br Med J 1944 ii 393–398.

    Google Scholar 

  3. Klopper A, Hall M. New synthetic agent for the induction of ovulation: preliminary trial in women. Br Med J 1971 2 152–154.

    Google Scholar 

  4. Jordan V. Antitumour activity of the antioestrogen ICI 46,474 (tamoxifen) in the dimethylbenzanthracene (DMBA)-induced rat mammary carcinoma model. J Steroid Biochem 1974 5 354 (abs).

    Google Scholar 

  5. Jensen E et al Oestrogen receptors and breast cancer response to adrenalectomy. Natl Cancer Inst Monogr 1971 34 55–70.

    CAS  PubMed  Google Scholar 

  6. Ward H. Anti-oestrogen therapy for breast cancer. A trial of tamoxifen at two dose levels. Br Med J 1973 1 13–14.

    CAS  PubMed  PubMed Central  Google Scholar 

  7. Cole M, Jones C, Todd J. A new antioestrogenic agent in late breast cancer: an early clinical trial. Br J Cancer 1971 25 270–275.

    CAS  PubMed  PubMed Central  Google Scholar 

  8. Zumoff B et al Abnormal 24-h mean plasma concentrations of dehydroisoandrosterone and dehydroisoandrosterone sulfate in women with primary operable breast cancer. Cancer Res 1981 41 3360–3363.

    CAS  PubMed  Google Scholar 

  9. Gordon GB et al Relationship of serum levels of dehydroepiandrosterone and dehydroepiandrosterone sulfate to the risk of developing postmenopausal breast cancer. Cancer Res 1990 50 3859–3862.

    CAS  PubMed  Google Scholar 

  10. McGuire W, Chmaness G. Studies on the oestrogen receptor in breast cancer. In: O'Malley B, Means A (eds). Receptors for Reproductive Hormones Plenum Publishing Corp: New York 1973 113–136.

    Google Scholar 

  11. Fisher B et al Treatment of primary breast cancer with chemotherapy and tamoxifen. New Engl J Med 1981 305 1–6.

    CAS  PubMed  Google Scholar 

  12. Fisher B et al Influence of tumour oestrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer. J Clin Oncol 1983 1 227–241.

    CAS  PubMed  Google Scholar 

  13. Fisher B et al Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project Trial. J Clin Oncol 1986 4 459–471.

    CAS  PubMed  Google Scholar 

  14. Mouridsen P et al Tamoxifen in advanced breast cancer. Cancer Treat Rev 1978 5 131–141.

    CAS  PubMed  Google Scholar 

  15. Horwitz K, McGuire W, Pearson O. Predicting response to endocrine therapy in human breast cancer: a hypothesis. Science 1975 189 726–727.

    CAS  PubMed  Google Scholar 

  16. Valavaara R, Tuominen J, Johansson R. Predictive value of tumour oestrogen and progesterone receptor levels in postmenopausal women with advanced breast cancer treated with toremifene. Cancer 1990 66 2264–2269.

    CAS  PubMed  Google Scholar 

  17. Ingle JN et al Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. New Engl J Med 1981 304 16–21.

    CAS  PubMed  Google Scholar 

  18. Westeberg H. Tamoxifen and fluoxymesterone in advanced breast cancer. Cancer Treat Rep 1980 64 117–121.

    Google Scholar 

  19. Ingle J et al Randomized clinical trial of megestrol acetate versus tamoxifen in paramenopausal or castrated women with advanced breast cancer. Am J Clin Oncol 1982 5 155–160.

    CAS  PubMed  Google Scholar 

  20. Ettinger D et al Megestrol acetate vs. tamoxifen in advanced breast cancer: correlation of hormone receptors and response. Semin Oncol 1986 13 (Suppl 4): 9–14.

    Google Scholar 

  21. Lipton A et al Randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer. Cancer Res 1982 42 (Suppl 8): 3434S–3436S.

    Google Scholar 

  22. Smith IE et al Tamoxifen versus aminoglutethimide versus combined tamoxifen and aminoglutethimide in the treatment of advanced breast carcinoma. Cancer Res 1982 42 (Suppl 8): 3430S–3433S.

    Google Scholar 

  23. Buchanan RB et al A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer. J Clin Oncol 1986 4 1326–1330.

    CAS  PubMed  Google Scholar 

  24. Ingle JN et al Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer. J Clin Oncol 1986 4 178–185.

    CAS  PubMed  Google Scholar 

  25. Nemoto T et al Tamoxifen (nolvadex) versus adrenalectomy in metastatic breast cancer. Cancer 1984 53 1333–1335.

    CAS  PubMed  Google Scholar 

  26. Hubay CA et al Adjuvant chemotherapy, anti-oestrogen therapy and immunotherapy for stage II breast cancer. Eur J Cancer 1980 (Suppl 1): 189–195.

  27. Palshof T, Mouridsen H, Daehnfeldt J. Adjuvant endocrine therapy of primary operable breast cancer. Report on the Copenhagen breast cancer trials. Eur J Cancer 1980 (Suppl 1): 183–187.

  28. Wallgren A et al Tamoxifen and combination chemotherapy as adjuvant treatment in postmenopausal women with breast cancer. Recent Results Cancer Res 1984 96 197–203.

    CAS  PubMed  Google Scholar 

  29. Baum M et al Improved survival among patients treated with adjuvant tamoxifen after mastectomy for early breast cancer. Lancet 1983 ii 450.

    Google Scholar 

  30. Breast Cancer Trials Committee (SCTO). Adjuvant tamoxifen in the management of operable breast cancer: the Scottish Trial. Report from the Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh. Lancet 1987 ii 171–175.

    Google Scholar 

  31. Pritchard KI, Sutherland D. The use of endocrine therapy. Hematol Oncol Clin North Am 1989 3 765–805.

    CAS  PubMed  Google Scholar 

  32. Senanayake F. Adjuvant hormonal chemotherapy in early breast cancer: early results from a controlled trial. Lancet 1984 ii 1148–1149.

    Google Scholar 

  33. Cummings F et al Adjuvant tamoxifen treatment of elderly women with stage II breast cancer. A double-blind comparison with placebo. Ann Intern Med 1985 103 324–329.

    CAS  PubMed  Google Scholar 

  34. Ludwig Breast Cancer Study Group. Randomised trial of chemo-endocrine therapy, endocrine therapy, and mastectomy alone in postmenopausal patients with operable breast cancer and axillary node metastasis. Lancet 1984 i 1256–1260.

    Google Scholar 

  35. Goldhirsch A, Gelber R. Adjuvant treatment for early breast cancer: the Ludwig breast cancer studies. NCI Monogr 1986 1 55–70.

    Google Scholar 

  36. CRC Adjuvant Breast Trial Working Party. Cyclophosphamide and tamoxifen as adjuvant therapies in the management of breast cancer. CRC Adjuvant Breast Trial Working Party. Br J Cancer 1988 57 604–607.

    Google Scholar 

  37. Fisher B et al A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have oestrogen-receptor-positive tumours. New Engl J Med 1989 320 479–484.

    CAS  PubMed  Google Scholar 

  38. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 1992 339 1–15, 71–85.

    Google Scholar 

  39. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998 352 930–942.

    Google Scholar 

  40. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998 351 1451–1467.

    Google Scholar 

  41. Gray R et al The EBCTCG overview of adjuvant therapy of breast cancer. What are the implications for future studies? Early Breast Cancer Trialists' Collaborative Group. Ann N Y Acad Sci 1993 698 339–348.

    CAS  PubMed  Google Scholar 

  42. Swedish Breast Cancer Cooperative Group. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. J Natl Cancer Inst 1996 88 1543–1549.

    Google Scholar 

  43. Current Trials Working Party of the Cancer Research Campaign Breast Cancer Trials Group. Preliminary results from the cancer research campaign trial evaluating tamoxifen duration in women aged fifty years or older with breast cancer. J Natl Cancer Inst 1996 88 1834–1839.

    Google Scholar 

  44. Fisher B et al Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and oestrogen receptor-positive tumours. J Natl Cancer Inst 1996 88 1529–1542.

    CAS  PubMed  Google Scholar 

  45. Tormey D, Gray R, Falkson H. Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. Eastern Cooperative Oncology Group. J Natl Cancer Inst 1996 88 1828–1833.

    CAS  PubMed  Google Scholar 

  46. Jordan V. Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinoma. Eur J Cancer 1976 12 419–424.

    CAS  PubMed  Google Scholar 

  47. Powles TJ. Status of antioestrogen breast cancer prevention trials. Oncology (Huntingt) 1998 12 28–31.

    CAS  Google Scholar 

  48. Fisher B et al Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998 90 1371–1388.

    CAS  PubMed  Google Scholar 

  49. Kristensen B et al Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study. J Clin Oncol 1994 12 992–997.

    CAS  PubMed  Google Scholar 

  50. Kristensen B et al Femoral fractures in postmenopausal breast cancer patients treated with adjuvant tamoxifen. Breast Cancer Res Treat 1996 39 321–326.

    CAS  PubMed  Google Scholar 

  51. McDonald CC, Stewart H. Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee. Br Med J 1991 303 435–437.

    CAS  Google Scholar 

  52. Rutqvist LE et al Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group. J Natl Cancer Inst 1993 85 1398–1406.

    CAS  PubMed  Google Scholar 

  53. Love RR et al Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with nodenegative breast cancer. J Natl Cancer Inst 1990 82 1327–1332.

    CAS  PubMed  Google Scholar 

  54. Satyaswaroop P, Zaino R, Mortel R. Oestrogen-like effects of tamoxifen on human endometrial carcinoma transplanted into nude mice. Cancer Res 1984 44 4006–4010.

    CAS  PubMed  Google Scholar 

  55. Fornander T et al Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1989 i 117–120.

    Google Scholar 

  56. Magriples U et al High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol 1993 11 485–490.

    CAS  PubMed  Google Scholar 

  57. Fisher B et al Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994 86 527–537.

    CAS  PubMed  Google Scholar 

  58. van Leeuwen FE et al Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 1994 343 448–452.

    CAS  PubMed  Google Scholar 

  59. Catherino W, Jordan V. A risk benefit assessment of tamoxifen therapy. Drug Safety 1993 8 381–397.

    CAS  PubMed  Google Scholar 

  60. Jordan V, Assikis V. Tamoxifen and endometrial cancer: clearing up a controversy. Clin Cancer Res 1995 1 467–472.

    CAS  PubMed  Google Scholar 

  61. Cummings SR et al Raloxifene reduces the risk of breast cancer and may decrease the risk of endometrial cancer in postmenopausal women. Two-year findings from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial. Proc Am Soc Clin Oncol 1998 17 2A (abs 3).

    Google Scholar 

  62. Jordan VC et al Incident primary breast cancers are reduced by raloxifene: integrated data from multicenter, double-blind, randomized trials in ∼12,000 postmenopausal women. Proc Am Soc Clin Oncol 1998 17 122A (abs 466).

    Google Scholar 

  63. Gradishar W et al Effects of high dose raloxifene in selected patients with advanced breast carcinoma. Cancer 2000 88 2047–2053.

    CAS  PubMed  Google Scholar 

  64. Jordan VC. Targeted antioestrogens to prevent breast cancer. Trends Endocrinol Metab 1999 10 312–317.

    CAS  PubMed  Google Scholar 

  65. Huggins C, Hodges C. Studies on prostatic cancer. 1. Effect of castration, of oestrogen and of androgen injections on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941 1 293–297.

    CAS  Google Scholar 

  66. Bailar JI, Byar D. Oestrogen treatment for cancer of the prostate. Early results with 3 doses of diethylstilbestrol and placebo. Cancer 1970 26 257–261.

    PubMed  Google Scholar 

  67. Blackard C et al Incidence of cardiovascular disease and death in patients receiving diethylstilbestrol for carcinoma of the prostate. Cancer 1970 26 249–256.

    CAS  PubMed  Google Scholar 

  68. Blackard C. The Veterans Administration Cooperative Urological Research Group studies of carcinoma of the prostate: a review. Cancer Treat Rep 1975 59 225–227.

    CAS  Google Scholar 

  69. Byar D, Corle D. Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies. Natl Cancer Inst Monogr 1988 7 165–170.

    Google Scholar 

  70. Schally A et al Isolation of properties of the FSH and LH-releasing hormone. Biophys Res Commun 1971 43 393–399.

    CAS  Google Scholar 

  71. Labrie F et al Combination therapy for prostate cancer. Endocrine and biologic basis of its choice as new standard first-line therapy. Cancer 1993 71 1059–1067.

    CAS  PubMed  Google Scholar 

  72. Peeling W. Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in the treatment of prostate cancer. Urology 1989 33 (Suppl 5): 45–52.

    Google Scholar 

  73. Soloway M et al Zoladex versus orchiectomy in the treatment of advanced prostate cancer. Urology 1991 37 46–51.

    CAS  PubMed  Google Scholar 

  74. Turkes A, Peeling W, Griffiths K. Treatment of patients with advanced cancer of the prostate: Phase II trial, Zoladex against castration; a study of the British Prostate Group. J Steroid Biochem 1987 27 543–549.

    CAS  PubMed  Google Scholar 

  75. Leuprolide Study Group. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. New Engl J Med 1984 311 1281–1286.

    Google Scholar 

  76. Sharifi R, Ray P, Lee M. Comparison of leuprolide and diethylstilbestrol for stage D2 adenocarcinoma of the prostate. Urology 1985 26 117–124.

    CAS  PubMed  Google Scholar 

  77. Kuhn JM et al Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide). New Engl J Med 1989 321 413–418.

    CAS  PubMed  Google Scholar 

  78. Maillefert JF et al Bone mineral density in men treated with synthetic gonadotrophin-releasing hormone agonists for prostatic carcinoma. J Urol 1999 161 1219–1222.

    CAS  PubMed  Google Scholar 

  79. Daniell HW. Osteoporosis after orchiectomy for prostate cancer. J Urol 1997 157 439–444.

    CAS  PubMed  Google Scholar 

  80. Johnson D et al Medical castration using megestrol acetate and minidose oestrogen. Urology 1988 31 371–374.

    CAS  PubMed  Google Scholar 

  81. Goldenberg SL et al The combination of cyproterone acetate and low dose diethylstilbestrol in the treatment of advanced prostatic carcinoma. J Urol 1988 140 1460–1465.

    CAS  PubMed  Google Scholar 

  82. Labrie C et al Analysis of the androgenic activity of synthetic ‘progestins’ currently used for the treatment of prostate cancer. J Steroid Biochem 1987 28 379–384.

    CAS  PubMed  Google Scholar 

  83. Sartor O, Eastham JA. Progressive prostate cancer associated with the use of megestrol acetate administered for control of hot flashes. South Med J 1999 92 415–416.

    CAS  PubMed  Google Scholar 

  84. Mahler C, Verhelst J, Denis L. Ketoconazole and liarozole in the treatment of advanced prostatic cancer. Cancer 1993 71 1068–1073.

    CAS  PubMed  Google Scholar 

  85. Venner P et al Megestrol acetate plus minidose diethylstilbestrol in the treatment of carcinoma of the prostate. Semin Oncol 1988 15 (Suppl 1): 62–67.

    PubMed  Google Scholar 

  86. de Voogt H et al Cardiovascular side effects of diethylstilbestrol, cyproteroneacetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on Treatment of Cancer trials 30761 and 30762. J Urol 1986 135 303–307.

    CAS  PubMed  Google Scholar 

  87. Crawford ED et al A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. New Engl J Med 1989 321 419–424.

    CAS  PubMed  Google Scholar 

  88. Belanger A, Brochu M, Cliche J. Levels of plasma steroid glucuronides in intact and castrated men with prostatic cancer. J Clin Endocrinol Metab 1986 62 812–815.

    CAS  PubMed  Google Scholar 

  89. Murray R, Pitt P. Treatment of advanced prostate cancer, resistant to conventional therapy. Eur J Cancer 1985 21 453–458.

    CAS  Google Scholar 

  90. Geller J et al Comparison of prostate cancer tissue dihydrotestosterone levels at the time of relapse following orchiectomy or oestrogen therapy. J Urol 1984 132 693–696.

    CAS  PubMed  Google Scholar 

  91. Geller J, Albert J. Adrenal androgen blockade in relapsed prostate cancer. Eur J Cancer Clin Oncol 1985 21 1127–1131.

    CAS  PubMed  Google Scholar 

  92. Geller J. Rationale for blockade of adrenal as well as testicular androgens in the treatment of advanced prostate cancer. Semin Oncol 1985 12 28–35.

    CAS  PubMed  Google Scholar 

  93. Harper M et al Steroids of adrenal origin metabolized by human prostatic tissue both in vivo and in vitro J Endocrinol 1974 60 117–125.

    CAS  PubMed  Google Scholar 

  94. Bracci U. Antiandrogens in the treatment of prostatic cancer. Eur Urol 1979 5 303–306.

    CAS  PubMed  Google Scholar 

  95. Labrie F et al Advantages of the combination therapy in previously untreated and treated patients with advanced prostate cancer. J Steroid Biochem 1986 25 877–883.

    CAS  PubMed  Google Scholar 

  96. Labrie F et al New hormonal treatment in cancer of the prostate: combined administration of an LHRH agonist and an antiandrogen. J Steroid Biochem 1983 19 999–1007.

    CAS  PubMed  Google Scholar 

  97. Labrie F et al Combined treatment with LHRH agonist and pure antiandrogen in advanced carcinoma of prostate. Lancet 1984 ii 1090.

    Google Scholar 

  98. Labrie F et al Simultaneous administration of pure antiandrogens, a combination necessary for the use of luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer. Proc Natl Acad Sci USA 1984 81 3861–3863.

    CAS  PubMed  PubMed Central  Google Scholar 

  99. Labrie F et al Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in advanced prostate cancer: a marked improvement in response and survival. J Steroid Biochem 1985 23 833–841.

    CAS  PubMed  Google Scholar 

  100. Labrie F et al Long term treatment with luteinising hormone releasing hormone agonists and maintenance of serum testosterone to castration concentrations. Br Med J (Clin Res Ed) 1985 291 369–370.

    CAS  Google Scholar 

  101. Labrie F et al Combination therapy in prostate cancer. Lancet 1986 ii 1095–1096.

    Google Scholar 

  102. Eisenberger MA et al Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. New Engl J Med 1998 339 1036–1042.

    CAS  PubMed  Google Scholar 

  103. Blackledge G. Casodex—mechanisms of action and opportunities for usage. Cancer 1993 72 3830–3833.

    CAS  PubMed  Google Scholar 

  104. Soloway M et al Bicalutamide in the treatment of advanced prostatic carcinoma: a phase II noncomparative multicenter trial evaluating safety, efficacy and long-term endocrine effects of monotherapy. J Urol 1995 154 2110–2114.

    CAS  PubMed  Google Scholar 

  105. Bales GT, Chodak G. A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology 1996 47 38–43.

    CAS  PubMed  Google Scholar 

  106. Kolvenbag G, Blackledge G, Gotting-Smith K. Bicalutamide (Casodex) in the treatment of prostate cancer: history of clinical development. Prostate 1998 72 61–72.

    Google Scholar 

  107. Schellhammer P et al Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Casodex Combination Study Group. Urology 1996 47 54–60.

    CAS  PubMed  Google Scholar 

  108. Schellhammer PF et al Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group. Urology 1997 50 330–336.

    CAS  PubMed  Google Scholar 

  109. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 2000 355 1491–1498.

    Google Scholar 

  110. Labrie F, Candas B. Androgen blockade in prostate cancer. Lancet 2000 356 341–342.

    CAS  PubMed  Google Scholar 

  111. Sarosdy MF et al Does prolonged combined androgen blockade have survival benefits over short-term combined androgen blockade therapy? Urology 2000 55 391–395.

    CAS  PubMed  Google Scholar 

  112. Tyrrell CJ et al A randomised comparison of ‘Casodex’ (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 1998 33 447–456.

    CAS  PubMed  Google Scholar 

  113. Iversen P et al Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 y of followup. J Urol 2000 164 1579–1582.

    CAS  PubMed  Google Scholar 

  114. Tyrrell CJ et al A randomised comparison of ‘Casodex’ (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 1998 33 447–456.

    CAS  PubMed  Google Scholar 

  115. Scher H et al Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. J Clin Oncol 1997 15 2928–2938.

    CAS  PubMed  Google Scholar 

  116. Joyce R et al High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy. J Urol 1998 159 149–153.

    CAS  PubMed  Google Scholar 

  117. Veldscholte J et al A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 1990 173 534–540.

    CAS  PubMed  Google Scholar 

  118. Tilley WD et al Detection of discrete androgen receptor epitopes in prostate cancer by immunostaining: measurement by color video image analysis. Cancer Res 1994 54 4096–4102.

    CAS  PubMed  Google Scholar 

  119. Fenton MA et al Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. Clin Cancer Res 1997 3 1383–1388.

    CAS  PubMed  Google Scholar 

  120. Scher HL et al Hormone and antihormone withdrawal: implications for the management of androgen-independent prostate cancer. Urology 1996 47 (Suppl 1A): 61–69.

    PubMed  Google Scholar 

  121. Kelly WK, Sloven S, Scher HI. Steroid hormone withdrawal syndromes. Pathophysiology and clinical significance. Urol Clin North Am 1997 24 421–431.

    CAS  PubMed  Google Scholar 

  122. Schellhammer PF et al Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade. J Urol 1997 157 1731–1735.

    CAS  PubMed  Google Scholar 

  123. Stein A et al Prostate-specific antigen levels after radical prostatectomy in patients with organ-confined and locally extensive prostate cancer. J Urol 1992 147 942–946.

    CAS  PubMed  Google Scholar 

  124. Schmidt JD, Gibbons RP, Murphy GP, Bartolucci A. Adjuvant therapy for clinical localized prostate cancer treated with surgery or irradiation. Eur Urol 1996 29 425–433.

    CAS  PubMed  Google Scholar 

  125. Bolla M et al Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. New Engl J Med 1997 337 295–300.

    CAS  PubMed  Google Scholar 

  126. Pilepich MV et al Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol 1997 15 1013–1021.

    CAS  PubMed  Google Scholar 

  127. Laverdière J et al Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys 1997 37 247–252.

    PubMed  Google Scholar 

  128. Wirth M et al Randomized multicenter trial on adjuvant flutamide therapy in locally advanced cancer after radical prostatectomy. Br J Urol 1997 80 (Suppl 2): 263 (abs).

    Google Scholar 

  129. Wirth M, Froehner M. A review of studies of hormonal adjuvant therapy in prostate cancer. Eur Urol 1999 36 (Suppl 2): 14–19.

    Google Scholar 

  130. Wirth M et al Bicalutamide (‘Casodex’) 150 mg as immediate or adjuvant therapy in 8113 men with localized or locally advanced prostate cancer. Proc Am Soc Clin Oncol 2001 20 177a (abs 705).

    Google Scholar 

  131. Gormely G. Chemoprevention strategies for prostate cancer: the role of 5 alpha-reductase inhibitors. J Cell Biochem 1992 16H (Suppl): 113–117.

    Google Scholar 

  132. Oesterling J. Benign prostatic hyperplasia. Medical and minimally invasive treatment options. New Engl J Med 1995 332 99–109.

    CAS  PubMed  Google Scholar 

  133. Thompson I, Coltman C, Crowley J. Chemoprevention of prostate cancer: The Prostate Cancer Prevention Trial. Prostate 1997 33 217–221.

    CAS  PubMed  Google Scholar 

  134. Cote RJ et al The effect of finasteride on the prostate gland in men with elevated serum prostate-specific antigen levels. Br J Cancer 1998 78 413–418.

    CAS  PubMed  PubMed Central  Google Scholar 

  135. Bostwick DG. Clinical utility of prostatic intraepithelial neoplasia. Mayo Clin Proc 1995 70 395–396.

    CAS  PubMed  Google Scholar 

  136. Kovi J et al Large acinar atypical hyperplasia and carcinoma of the prostate. Cancer 1988 61 555–561.

    CAS  PubMed  Google Scholar 

  137. Sakr W et al The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol 1993 150 379–385.

    CAS  PubMed  Google Scholar 

  138. Ferguson J et al Decrease of prostatic intraepithelial neoplasia (PIN) following androgen deprivation therapy in patients with stage T3 carcinoma treated by radical prostatectomy. Urology 1994 44 91–95.

    CAS  PubMed  Google Scholar 

  139. Sweat S et al Androgen receptor expression in prostate cancer lymph node metastases is predictive of outcome after surgery. J Urol 1999 161 1233–1237.

    CAS  PubMed  Google Scholar 

  140. Sweat SD et al Androgen receptor expression in prostatic intraepithelial neoplasia and cancer. J Urol 1999 161 1229–1232.

    CAS  PubMed  Google Scholar 

  141. Palmberg C et al Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer. J Urol 2000 164 1992–1995.

    CAS  PubMed  Google Scholar 

  142. Bubendorf L et al Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res 1999 59 803–806.

    CAS  PubMed  Google Scholar 

  143. Klijn J et al A new standard treatment for advanced premenopausal breast cancer: a meta-analysis of the Combined Hormonal Agent Trialists' Group. Eur J Cancer 1998 34 (Suppl 5): S90 (abs 405).

    Google Scholar 

  144. Messing EM et al Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. New Engl J Med 1999 341 1781–1788.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

D Lawrence Wickerham, MD is acknowledged for critical review of the manuscript.

Author information

Authors and Affiliations

  1. The Midwest Prostate and Urology Health Center, Chicago, IL, USA

    GW Chodak

  2. AstraZeneca, Wilmington, DE, USA

    GJCM Kolvenbag

Authors
  1. GW Chodak
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. GJCM Kolvenbag
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chodak, G., Kolvenbag, G. Will the experience with tamoxifen in breast cancer help define the role of antiandrogens in prostate cancer?. Prostate Cancer Prostatic Dis 4, 72–80 (2001). https://doi.org/10.1038/sj.pcan.4500518

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.pcan.4500518

Keywords

Search

Advanced search

Quick links